Spyre Therapeutics (SYRE) Profit After Tax: 2015-2025
Historic Profit After Tax for Spyre Therapeutics (SYRE) over the last 11 years, with Sep 2025 value amounting to -$11.2 million.
- Spyre Therapeutics' Profit After Tax rose 83.80% to -$11.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$149.0 million, marking a year-over-year increase of 30.68%. This contributed to the annual value of -$208.0 million for FY2024, which is 38.60% up from last year.
- According to the latest figures from Q3 2025, Spyre Therapeutics' Profit After Tax is -$11.2 million, which was up 69.54% from -$36.7 million recorded in Q2 2025.
- Spyre Therapeutics' 5-year Profit After Tax high stood at -$6.8 million for Q2 2021, and its period low was -$217.1 million during Q2 2023.
- Moreover, its 3-year median value for Profit After Tax was -$43.9 million (2024), whereas its average is -$58.1 million.
- As far as peak fluctuations go, Spyre Therapeutics' Profit After Tax slumped by 872.45% in 2023, and later spiked by 83.80% in 2025.
- Over the past 5 years, Spyre Therapeutics' Profit After Tax (Quarterly) stood at -$20.4 million in 2021, then climbed by 7.94% to -$18.8 million in 2022, then crashed by 235.67% to -$63.2 million in 2023, then grew by 10.90% to -$56.3 million in 2024, then skyrocketed by 83.80% to -$11.2 million in 2025.
- Its Profit After Tax stands at -$11.2 million for Q3 2025, versus -$36.7 million for Q2 2025 and -$44.8 million for Q1 2025.